- Posts: 135
- Thank you received: 76
Treatment over waiting for SVR
it's good enough to be considered the same for generic purposes, but it is less
Thanks for that information, don't like the sounds of" but it is less". Do you think I should increase Sosobuvir a bit, I do have a pill cutter
For something to qualify as a generic it must show similar pharmacokinetic properties (in English similar blood levels at different points of time after taking it). You will find all the nitty gritty here:
The Form I vs Form II argument is probably irrelevant to clinical results but it remains a fact that Form I was what was used in the Phase 3 trials everyone reads and Form II is what is used in the commercial product.
It is unlikely to make a significant difference. A 50 kg person is getting 150% of the dose an average 75 kg person gets in mg/kg terms. A 150 kg person is getting only 50% in mg/kg terms. Provided the therapeutic window is wide enough dose adjustment is not required and a one size fits all dose is fine.
That said my eyes nearly fell out of my head when I saw that Gilead had changed from using what was tested to something that was not tested in the same way (Phase 3) but rather in the same way a generic is declared bio-identical.
One more point Doc, those Hep organisations should have picked this deception up.(there is enough of them spread across the country) Its wrong that we are only learning about it now. We have a right to know. The public has a right to know. This must be a new news worthy story. kindly
- Posts: 383
- Thank you received: 659
I'm a 96 kg 3a non responder with a knocked around liver but have had a great response with Sof and Dac regular dose so far. Week 2 bloods Alt Ast within range V/L 19 mill down to 16.
Two time relapser.
SVR 4 achieved 12/16 at last
SVR 12 achieved 22/02/2017 The Bastard has been defeated
GT 3 - about 28 yrs with HCV
1b is the easiest genotype to treat with DAAs and can be done in 3 weeks with 3 DAAs
See LB-23 here....
Simeprevir is already listed so 1/4 of a course of Harvoni and 1/4 a course of Olysio looks like it will do the trick for RVR patients.
AbbVie and Viekira Pak are more civilized in their PBS negotiations. Better ? It just got a black box FDA warning....
We, as in Australia do not need all the manufacturers products.
We, as in Australia should invite those Pharma companies who want our TAX DOLLARS to sharpen their pencils.
We, as in Australia should cure as many patients now as we can afford.
Hypothetically why not cut a deal with one?
That would be infinity percent more patients getting treatment. Currently it is a division by zero error.